These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 16455806

  • 1. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
    Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW.
    Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
    [Abstract] [Full Text] [Related]

  • 2. Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells.
    Sawada GA, Raub TJ, William Higgins J, Brennan NK, Moore TM, Tombline G, Detty MR.
    Bioorg Med Chem; 2008 Nov 15; 16(22):9745-56. PubMed ID: 18849167
    [Abstract] [Full Text] [Related]

  • 3. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
    Keogh JP, Kunta JR.
    Eur J Pharm Sci; 2006 Apr 15; 27(5):543-54. PubMed ID: 16406207
    [Abstract] [Full Text] [Related]

  • 4. Rational use of in vitro P-glycoprotein assays in drug discovery.
    Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.
    J Pharmacol Exp Ther; 2001 Nov 15; 299(2):620-8. PubMed ID: 11602674
    [Abstract] [Full Text] [Related]

  • 5. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM.
    Drug Metab Dispos; 2008 Feb 15; 36(2):268-75. PubMed ID: 17962372
    [Abstract] [Full Text] [Related]

  • 6. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG.
    J Pharmacol Exp Ther; 2002 Oct 15; 303(1):323-32. PubMed ID: 12235267
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, Fong WF.
    Biochem Pharmacol; 2006 Sep 28; 72(7):824-37. PubMed ID: 16889754
    [Abstract] [Full Text] [Related]

  • 10. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
    Varma MV, Sateesh K, Panchagnula R.
    Mol Pharm; 2005 Sep 28; 2(1):12-21. PubMed ID: 15804173
    [Abstract] [Full Text] [Related]

  • 11. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
    Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G.
    J Pharmacol Exp Ther; 2001 Feb 28; 296(2):584-91. PubMed ID: 11160647
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?
    Lumen AA, Acharya P, Polli JW, Ayrton A, Ellens H, Bentz J.
    Drug Metab Dispos; 2010 Feb 28; 38(2):260-9. PubMed ID: 19889884
    [Abstract] [Full Text] [Related]

  • 14. Calcein assay: a high-throughput method to assess P-gp inhibition.
    Glavinas H, von Richter O, Vojnits K, Mehn D, Wilhelm I, Nagy T, Janossy J, Krizbai I, Couraud P, Krajcsi P.
    Xenobiotica; 2011 Aug 28; 41(8):712-9. PubMed ID: 21657832
    [Abstract] [Full Text] [Related]

  • 15. Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds.
    Szerémy P, Pál A, Méhn D, Tóth B, Fülöp F, Krajcsi P, Herédi-Szabó K.
    J Biomol Screen; 2011 Jan 28; 16(1):112-9. PubMed ID: 21057029
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
    Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA.
    Clin Pharmacol Ther; 2009 Feb 28; 85(2):173-81. PubMed ID: 18987624
    [Abstract] [Full Text] [Related]

  • 18. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
    Bachmeier CJ, Trickler WJ, Miller DW.
    Drug Metab Dispos; 2006 Jun 28; 34(6):998-1003. PubMed ID: 16554372
    [Abstract] [Full Text] [Related]

  • 19. From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example.
    Woodland C, Koren G, Ito S.
    J Clin Pharmacol; 2003 Jul 28; 43(7):743-50. PubMed ID: 12856388
    [Abstract] [Full Text] [Related]

  • 20. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
    Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.
    J Med Chem; 2003 Apr 24; 46(9):1716-25. PubMed ID: 12699389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.